An update on adjuvant systemic therapies in melanoma.
AJCC
adjuvant treatment
immunotherapy
interferon
ipilimumab
stage 3 melanoma
targeted therapy
Journal
Melanoma management
ISSN: 2045-0885
Titre abrégé: Melanoma Manag
Pays: England
ID NLM: 101649842
Informations de publication
Date de publication:
13 Nov 2019
13 Nov 2019
Historique:
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
7
12
2019
Statut:
epublish
Résumé
There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.
Identifiants
pubmed: 31807279
doi: 10.2217/mmt-2019-0009
pmc: PMC6891936
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
MMT28Informations de copyright
© 2019 Evangeline Samuel.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
J Clin Oncol. 2010 May 10;28(14):2452-9
pubmed: 20368546
Melanoma Res. 1992 Jan-Feb;1(5-6):311-25
pubmed: 1384854
J Clin Oncol. 2018 Oct 22;:JCO1801219
pubmed: 30343620
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Cancer. 2007 Feb;7(2):95-106
pubmed: 17251916
J Clin Oncol. 1996 Jan;14(1):7-17
pubmed: 8558223
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Clin Oncol. 2012 Nov 1;30(31):3810-8
pubmed: 23008300
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Ann Oncol. 2010 Aug;21(8):1712-7
pubmed: 20147741
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Lancet Oncol. 2018 Apr;19(4):510-520
pubmed: 29477665
Eur J Cancer. 2012 Jan;48(2):218-25
pubmed: 22056637
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Cochrane Database Syst Rev. 2013 Jun 18;(6):CD008955
pubmed: 23775773
Ann Surg. 2010 Sep;252(3):460-5; discussion 465-6
pubmed: 20739846
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Lancet Oncol. 2016 Jun;17(6):757-767
pubmed: 27161539
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Clin Cancer Res. 2004 Mar 1;10(5):1670-7
pubmed: 15014018
J Clin Oncol. 2013 Feb 1;31(4):499-506
pubmed: 23248252
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494